COVİD-19 BAĞLAMINDA SAĞLIK HİZMETLERİNDE MALİYET ETKİLİLİK ÇALIŞMALARINA YÖNELİK İNCELEME

Öz

Bu çalışmada COVID-19 pandemi sürecinde korunma, önleme, kontrol altına alma ve tedavi etmeye ilişkin maliyet-etkililik çalışmalarının bibliyometrik olarak gözden geçirilmesi ve genel bir bakış sunulması amaçlanmıştır. Araştırmanın örneklemi, 2020'den 2023 Eylül ayına kadar Web Of Science veri tabanında Social Science Citation Indexinde taranan 3334 makaleden oluşmaktadır. Elde edilen veri seti, analiz için VOSviewer 1.6.19 yazılımı kullanılarak incelenmiştir. Çalışmaların en fazla sayıda (1144) 2020 yılında yayımlandığı, en çok atıfın ise (7458) 2022 yılında gerçekleştiği ve bu çalışmaların %99,4'ünün (3315) İngilizce dilinde olduğu belirlenmiştir. Ağ haritasına göre, en çok kullanılan anahtar kelime "cost-effectiveness" (maliyet-etkililik) olmuştur. Diğer önemli anahtar kelimeler arasında "covid-19", "cost", "china", "tuberculosis", "child health", "telehealth", "non-small cell lung cancer", "treatment" ve "machine learning" bulunmaktadır. Dergi ortak atıf ağında en çok atıf alan dergi "Value in Health" olup, en yüksek bağlantı gücüne sahiptir (3405 atıf, 88386 bağlantı gücü). En çok atıf yapılan belgelerin Dünya Sağlık Örgütü'ne (DSÖ) ait iki farklı belge olduğu tespit edilmiştir (836-525 atıf). Ülke işbirliğinde en yüksek bağlantı gücüne sahip ülke "İngiltere"dir (1489 bağlantı gücü). Sonuç olarak, sağlık hizmetlerinde maliyet-etkililik çalışmalarının COVID-19'un yayılmasıyla etkilendiği ve bu konunun yakın tarihli çalışmaların anahtar kelimeleri arasında yer aldığı görülmektedir.

Anahtar Kelimeler

• Maliyet Etkililik
• Sağlık Hizmetleri
• Covid-19
• Bibliyometrik Analiz

REVIEW OF COST-EFFECTİVE STUDİES IN HEALTH CARE IN THE CONTEXT OF COVİD-19

Öz

This study aims to bibliometrically review and provide an overview of cost-effectiveness studies on protection, prevention, control and treatment during the COVID-19 pandemic process. The sample of the research consists of 3334 articles scanned in the Social Science Citation Index in the Web Of Science database from 2020 to September 2023. The resulting data set was examined using VOSviewer 1.6.19 software for analysis. It was determined that the largest number of studies (1144) were published in 2020, the most citations (7458) occurred in 2022, and 99.4% (3315) of these studies were in English. According to the network map, the most used keyword was "cost-effectiveness". Other important keywords include "covid-19", "cost", "china", "tuberculosis", "child health", "telehealth", "non-small cell lung cancer", "treatment" and "machine learning" . The most cited journal in the journal co-citation network is "Value in Health" and has the highest link strength (3405 citations, 88386 link strength). It was determined that the most cited documents were two different documents belonging to the World Health Organization (WHO) (836-525 citations). The country with the highest link strength in country collaboration is "England" (1489 link strength). As a result, it appears that cost-effectiveness studies in healthcare have been affected by the spread of COVID-19 and this issue is among the keywords of recent studies.

Anahtar Kelimeler

• Cost-effectiveness
• healthcare
• covid-19
• bibliometric analysis

Kaynakça

1. Bartsch, S.M., Ferguson, M.C., McKinnell, J.A., O’Shea, K.J., Wedlock, P.T., Siegmund, S.S. & Lee, B. Y. (2020). The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. Health affairs, 39 (6), 927-935.
2. Burgos, R. M., Badowski, M. E., Drwiega, E., Ghassemi, S., Griffith, N., Herald, F., Johnson, M.,. O Smith, R. & Michienzi, S. M. (2021). The race to a COVID-19 vaccine: Opportunities and challenges in development and distribution. Drugs in context, 10.
3. Donthu, N., Kumar, S., Mukherjee, D., Pandey, N., & Lim, W. M. (2021). How to conduct a bibliometric analysis: An overview and guidelines. Journal of business research, 133, 285-296.
4. Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes (Third Edit.). United States: Oxford university press.
5. Kickbusch, I., Leung, G. M., Bhutta, Z. A., Matsoso, M. P., Ihekweazu, C., & Abbasi, K. (2020). Covid-19: how a virus is turning the world upside down. BMJ, 369.
6. Kristensen, F.B. (2008) Transnational Collaboration on Health Technology Assessment – A Political Priority in Europe. M.V. Garrido, F.B. Kristensen, C.P. Nielsen ve R. Busse (Ed.). Health Technology Assessment and Health Policy Making in Europe – Current Status, Challenges and Potential içinde. Observatory Series No: 14. Geneva: WHO.
7. Mullins, C. D., & Drummond, M. F. (2020). The role of health economics and outcomes research in addressing coronavirus disease 2019 (COVID-19). Value in Health, 23 (11), 1403-1404.
8. Nielsen C.P., Santamera A.S. and Vondeling H. (2008) Policy Process and Health Technology Assessment. M.V. Garrido F.B. Kristensen C.P. Nielsen and R. Busse (Ed.). Health Technology Assessment and Health Policy Making in Europe – Current Status, Challenges and Potential içinde. Observatory Series No:14. United Kingdom: WHO.

9. World Health Organization. Coronavirus disease (COVID-19). Secondary Coronavirus disease (COVID-19). Erişim Tarihi: 1 Mart 2024, https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
10. Shen, M., Zu, J., Fairley, C. K., Pagán, J. A., An, L., Du, Z., Guo, Y., Rong, Y. Xiao, Y., Zhuang, G. & Zhang, L. (2021). Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use. Vaccine, 39 (16), 2295-2302.
11. Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., Fu, S., Gao, L., Cheng, Z., Lu, Q., Hu, Y., Luo, G., Wang, K., Lu, Y., Li, H., Wang, S., Ruan, S.,Yang, C., Mei, C., Wang, Y., Ding, D., Wu, F., Tang, X., Ye, X., Ye, Y., Liu, B., Yang, J., Yin, W., Wang, A., Fan, G., Zhou, F., Liu, Z., Gu, X., Xu, J., Shang, L., Zhang, Y., Cao, L., Guo, T., Wan, Y., Qin, H., Jiang, Y., Jaki, T. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet, 395 (10236), 1569-1578.
12. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu, S., Zhao, P., Liu, P., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., Wang, F.S.(2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8 (4), 420-422.